BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34610104)

  • 1. Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials.
    Valtis YK; Stevenson KE; Place AE; Silverman LB; Vrooman LM; Gotti G; Brunner AM; Nauffal M; DeAngelo DJ; Luskin MR
    Blood Adv; 2022 Jan; 6(1):72-81. PubMed ID: 34610104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.
    Vrooman LM; Stevenson KE; Supko JG; O'Brien J; Dahlberg SE; Asselin BL; Athale UH; Clavell LA; Kelly KM; Kutok JL; Laverdière C; Lipshultz SE; Michon B; Schorin M; Relling MV; Cohen HJ; Neuberg DS; Sallan SE; Silverman LB
    J Clin Oncol; 2013 Mar; 31(9):1202-10. PubMed ID: 23358966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001.
    Kahn JM; Cole PD; Blonquist TM; Stevenson K; Jin Z; Barrera S; Davila R; Roberts E; Neuberg DS; Athale UH; Clavell LA; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJG; Sallan SE; Silverman LB; Kelly KM
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.
    Barry E; DeAngelo DJ; Neuberg D; Stevenson K; Loh ML; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin M; Cohen HJ; Sallan SE; Silverman LB
    J Clin Oncol; 2007 Mar; 25(7):813-9. PubMed ID: 17327603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials.
    Shimony S; Flamand Y; Valtis YK; Place AE; Silverman LB; Vrooman LM; Brunner AM; Sallan SE; Stone RM; Wadleigh M; Neuberg DS; DeAngelo DJ; Luskin MR
    Blood Adv; 2023 Sep; 7(18):5234-5245. PubMed ID: 37432068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.
    Vrooman LM; Blonquist TM; Stevenson KE; Supko JG; Hunt SK; Cronholm SM; Koch V; Kay-Green S; Athale UH; Clavell LA; Cole PD; Harris MH; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Place AE; Schorin MA; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
    J Clin Oncol; 2021 Nov; 39(31):3496-3505. PubMed ID: 34228505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.
    Douer D; Aldoss I; Lunning MA; Burke PW; Ramezani L; Mark L; Vrona J; Park JH; Tallman MS; Avramis VI; Pullarkat V; Mohrbacher AM
    J Clin Oncol; 2014 Mar; 32(9):905-11. PubMed ID: 24516026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of children and adolescents with Down syndrome treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00-001 and 05-001.
    Athale UH; Puligandla M; Stevenson KE; Asselin B; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Harris MH; Neuberg DS; Sallan SE; Silverman LB
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27256. PubMed ID: 29878490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.
    Silverman LB; Gelber RD; Dalton VK; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Arkin S; Declerck L; Cohen HJ; Sallan SE
    Blood; 2001 Mar; 97(5):1211-8. PubMed ID: 11222362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective study of Dana Farber Consortium Protocol in newly diagnosed Egyptian adolescents and young adults with acute lymphoblastic leukemia: Tanta experience.
    Elashtokhy HEA; Elgohary HE; Eldeep BB; Gaber SM; Elbedewy TA
    J Egypt Natl Canc Inst; 2021 Apr; 33(1):9. PubMed ID: 33826046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Two Pediatric-Inspired Regimens to Hyper-CVAD in Hispanic Adolescents and Young Adults With Acute Lymphoblastic Leukemia.
    Almanza-Huante E; Espinosa-Bautista K; Rangel-Patiño J; Demichelis-Gómez R
    Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):55-62.e2. PubMed ID: 32893130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial.
    Mattano LA; Devidas M; Nachman JB; Sather HN; Hunger SP; Steinherz PG; Gaynon PS; Seibel NL;
    Lancet Oncol; 2012 Sep; 13(9):906-15. PubMed ID: 22901620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000).
    Silverman LB; Stevenson KE; O'Brien JE; Asselin BL; Barr RD; Clavell L; Cole PD; Kelly KM; Laverdiere C; Michon B; Schorin MA; Schwartz CL; O'Holleran EW; Neuberg DS; Cohen HJ; Sallan SE
    Leukemia; 2010 Feb; 24(2):320-34. PubMed ID: 20016537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Dana Farber Consortium Protocol for the Treatment of Adolescents and Young Adults With Acute Lymphoblastic Leukemia: A Single Institution Experience in Saudi Arabia.
    Alabdulwahab AS; Elsayed HG; Sherisher MA; Elbjeirami WM; Alieldin N
    Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):320-325. PubMed ID: 28343905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.
    DeAngelo DJ; Stevenson KE; Dahlberg SE; Silverman LB; Couban S; Supko JG; Amrein PC; Ballen KK; Seftel MD; Turner AR; Leber B; Howson-Jan K; Kelly K; Cohen S; Matthews JH; Savoie L; Wadleigh M; Sirulnik LA; Galinsky I; Neuberg DS; Sallan SE; Stone RM
    Leukemia; 2015 Mar; 29(3):526-34. PubMed ID: 25079173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.
    Ribera JM; Oriol A; Sanz MA; Tormo M; Fernández-Abellán P; del Potro E; Abella E; Bueno J; Parody R; Bastida P; Grande C; Heras I; Bethencourt C; Feliu E; Ortega JJ
    J Clin Oncol; 2008 Apr; 26(11):1843-9. PubMed ID: 18398150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health care utilisation and costs associated with different treatment protocols for newly diagnosed childhood acute lymphoblastic leukaemia: A population-based study in Ontario, Canada.
    Gupta S; Sutradhar R; Li Q; Athale U; Bassal M; Breakey V; Gibson PJ; Patel S; Silva M; Zabih V; Pechlivanoglou P; Pole JD; Mittmann N
    Eur J Cancer; 2021 Jul; 151():126-135. PubMed ID: 33979728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemia.
    Mogensen SS; Harila-Saari A; Mäkitie O; Myrberg IH; Niinimäki R; Vestli A; Hafsteinsdottir S; Griškevicius L; Saks K; Hallböök H; Retpen J; Helt LR; Toft N; Schmiegelow K; Frandsen TL;
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27300. PubMed ID: 29943905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Geyer MB; Ritchie EK; Rao AV; Vemuri S; Flynn J; Hsu M; Devlin SM; Roshal M; Gao Q; Shukla M; Salcedo JM; Maslak P; Tallman MS; Douer D; Park JH
    Haematologica; 2021 Aug; 106(8):2086-2094. PubMed ID: 33054114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.